Inside GRAPPA

In this special episode of Inside GRAPPA, we delve into the growing impact of the Patient Research Partner (PRP) Network—an essential part of GRAPPA's mission to integrate the patient voice into scientific research on psoriatic disease.Host Fabian Proft is joined by two influential PRPs: Maarten de Wit from the Netherlands and Suzanne Grieb* from the United States. Together, they explore the critical role of PRPs, the evolution of the network since its inception in 2013, and how these dedicated patient collaborators are shaping treatment guidelines, influencing steering committees, and helping recruit the next generation of partners.What does it really mean to live the principle of “Nothing about us without us”? What kinds of challenges—and transformative insights—do patients bring to the research table? And what can researchers learn from patient partners about improving outcomes, communication, and the research agenda itself?Listen in as we discuss:The origins and global growth of the PRP networkReal-world experiences from PRPs living with psoriatic arthritisHow patients are steering research priorities, not just participating in themStrategies for recruiting and onboarding new patient partnersWhere the network is headed—and how you might get involved

In this compelling episode of Inside GRAPPA, host Dr. Hanna Johnsson, a rheumatologist based in Scotland, leads an important conversation on one of the most pressing issues in psoriatic arthritis (PsA) care: what truly makes a case difficult to treat or complex to manage?Dr. Johnsson is joined by two experts deeply embedded in the GRAPPA initiative to define these concepts:Dr. Fabian Proft, Head of the Division of Rheumatology at Charité Berlin, Germany, and long-time GRAPPA contributor.Dr. Shikha Singla, Assistant Professor of Medicine at the Medical College of Wisconsin, who brings firsthand experience from her combined rheum-derm clinic.Together, they unpack the background, progress, and patient-centered approach of the Difficult-to-Treat (D2T) and Complex-to-Manage PsA Project.✅ HighlightsClearer definitions aim to improve care for patients with persistent symptoms despite treatment“Difficult to treat” focuses on ongoing inflammation; “complex to manage” accounts for non-inflammatory factorsA global literature review revealed inconsistent criteria in defining treatment challengesSurveys of clinicians and patients shaped a more inclusive, consensus-driven frameworkNew definitions to be presented at EULAR—marking a major milestone in PsA research⏱ Timestamps00:00 – Introduction to the episode and today's topic00:36 – Guest introductions: Dr. Fabian Proft and Dr. Shikha Singla01:00 – Fabian on the need for better definitions and understanding treatment failure04:12 – Defining the terms: inflammation vs. non-inflammatory drivers of disease burden05:15 – Why “complex to manage” is more appropriate than “difficult patient”06:00 – How terminology shapes perceptions and supports more empathetic care06:42 – Scoping literature review: methods and inconsistencies in existing definitions07:57 – Healthcare provider survey: over 200 responses, strong support for two definitions09:12 – Patient survey: nearly 600 responses and insights into global experiences10:21 – Patient-reported challenges: joint pain, fatigue, medication side effects11:54 – Cultural and social factors influencing patient experience12:39 – The Delphi process and achieving expert consensus13:15 – Project milestones: EULAR submission and upcoming publications

How do biological sex differences shape the clinical presentation and treatment outcomes in psoriatic arthritis (PsA)? In this episode of Inside GRAPPA, Dr. Hanna Johnsson delves into groundbreaking research led by Steven Dang and Dr. Lihi Eder, supported by the GRAPPA Pilot Research Grant. Their study explores sex-related differences in PsA through proteomic analysis, uncovering unique biomarkers and pathways that could redefine personalized medicine for PsA patients.What You'll Learn:The rationale behind investigating sex-specific differences in PsA. Insights into how immune and inflammatory profiles differ between males and females. Key findings from proteomic studies, including pivotal proteins and pathways like NETosis, Rho GTPase, and cytokine signaling. The potential for sex-specific biomarkers to guide diagnosis and treatment in PsA.

In this episode of Inside GRAPPA, Dr. Joel Gelfand joins host Mio Nakamura to discuss a groundbreaking pragmatic trial that may transform access to phototherapy. A long-standing GRAPPA member and trailblazer in dermatologic research, Dr. Gelfand shares insights from the "LITE Study," a patient-centered, nationwide trial comparing home-based vs. office-based phototherapy for psoriasis.You'll hear: • Why phototherapy remains a preferred treatment for many patients, even in the biologic era • Surprising results comparing office phototherapy to adalimumab (a biologic) in previous trials • How skin of color patients may benefit most from home phototherapy---and why • Real-world barriers to accessing phototherapy and how the study tackled them head-on • What's next: From research findings to implementation science and changing payer coverageThis episode is essential listening for dermatologists, rheumatologists, and researchers passionate about improving access and outcomes for patients with psoriatic disease. Tune in for a conversation that blends clinical science with patient advocacy---and may reshape the standard of care.

How does multimorbidity impact the progression from psoriasis to psoriatic arthritis? Can early identification of chronic conditions help prevent psoriatic arthritis in high-risk patients?In this episode of Inside GRAPPA, host Dr. Mio Nakamura sits down with Dr. Paras Karmacharya, recipient of a GRAPPA Annual Pilot Research Grant. He presented his findings at the 2024 GRAPPA Annual in Seattle and shares his groundbreaking study with us on "Multimorbidity and Psoriasis as a Risk Factor for Psoriatic Arthritis." Dr. Karmacharya discusses his personal journey into psoriatic arthritis research, how his study leveraged the Rochester Epidemiology Project, and what the findings mean for the future of patient care. He also explores: ✔️ What multimorbidity really means in psoriatic disease ✔️ The connection between chronic conditions and psoriatic arthritis risk ✔️ How his study design helped uncover key insights ✔️ The clinical implications for screening, early intervention, and patient educationKey Takeaways

What if we could predict psoriatic arthritis before it even begins? In this episode of Inside GRAPPA, host Dr. Hanna Johnson is joined by Professors Oliver Fitzgerald and Steve Pennington to discuss the groundbreaking HIPPOCRATES Project. Funded by the Innovative Healthcare Initiative, this major European research effort is tackling the biggest challenges in psoriatic arthritis (PsA)—from early diagnosis to precision treatment.With 27 partners across academia, industry, and patient organizations, HIPPOCRATES is at the forefront of multi omics research, integrating cutting-edge genomics, proteomics, and imaging technologies to revolutionize PsA care. But what are the biggest hurdles they've faced? And how close are they to real-world clinical impact?

In this episode, host Dr. Fabian Proft explores the most impactful research and updates from the EADV 2024 Congress in Amsterdam. Joining him are distinguished Young GRAPPA members Dr. Dimitri Luz, Dr. Ahmet Uğur, and Dr. Margo Gkini, who each share their expert perspectives on groundbreaking studies and their implications for psoriatic disease care.Episode Highlights:What the latest research reveals about psoriasis pathophysiology. How biologics are impacting long-term treatment safety and efficacy. Insights into the gut-skin connection and its role in inflammation.Resources and Links: Learn more about GRAPPA: GRAPPA Official Website Discover highlights from the GRAPPA EADV 2024 Congress Highlights.

How close are we to predicting psoriatic arthritis (PsA) before it strikes? In this episode of Inside GRAPPA, Dr. Fabian Proft sits down with two esteemed researchers, Dr. Axel Svedbom and Professor Mona Ståhle, from the Karolinska Institute in Stockholm, to discuss their groundbreaking study on predicting PsA in patients with new-onset psoriasis. Funded by the GRAPPA Pilot Research Grant, this project is poised to revolutionize early detection and intervention strategies for psoriatic disease.Listen as they discuss: The innovative predictive models combining machine learning with clinical data. Key findings, including the significance of arthralgia as a predictive marker for PsA. How their research could reshape clinical practices and improve patient outcomes.Featured Guests Dr. Axel Svedbom: Postdoctoral researcher specializing in registry-based research and health economics, with over a decade of focus on psoriasis and psoriatic arthritis. Professor Mona Ståhle: Dermatologist and researcher dedicated to advancing understanding and treatment of psoriatic disease.Resources & Links Stay updated with GRAPPA's initiatives: GRAPPA Website. Explore previous episodes of Inside GRAPPA: Podcast Archive.

How should musculoskeletal symptoms in psoriasis patients be managed---and who should take the lead? In this episode of Inside GRAPPA, Dr. Mio Nakamura moderates a compelling debate featuring Dr. Laura Savage, Consultant Dermatologist from Leeds Teaching Hospital, UK, and Dr. Fabian Proft, Rheumatologist from Berlin, Germany. Together, they tackle the vital question: Should dermatologists or rheumatologists be in the driver's seat when managing psoriatic arthritis (PsA)?Listen as they discuss: The role of dermatologists in early detection and PsA prevention. Rheumatologists' emphasis on precise diagnosis and targeted treatment. The power of collaborative care in improving patient outcomes.Join us for an engaging conversation about the challenges and opportunities in PsA management, and how multidisciplinary approaches can lead to better care for patients with psoriatic disease.Featured Guests Dr. Laura Savage: Consultant Dermatologist specializing in psoriatic disease, advocating for early intervention strategies in dermatology. Dr. Fabian Proft: Rheumatologist with expertise in imaging and precision medicine for inflammatory arthritis.Resources & Links Discover GRAPPA's commitment to collaboration: GRAPPA Website. Catch up on past episodes of Inside GRAPPA: Podcast Archive.

In this insightful episode, host Dr. Sebastian Herrera delves into the critical topic of comorbidities and related conditions in psoriatic disease, alongside experts Professor Kurt de Vlam MD, PhD, Head of Clinic Rheumatology at the University Hospitals Leuven in Belgium and Dr. Alexis Ogdie, MD, MSCE, Associate Professor of Medicine and Epidemiology at the University of Pennsylvania in the United States.What's inside this episode?Understanding Comorbidities vs. Related Conditions: Discover the distinctions between these two critical aspects and why it's important to differentiate them in psoriatic disease management.Expert Insights: Hear about the influence of comorbidities on treatment choices and patient outcomes.Impact on Treatment: Learn how related conditions and comorbidities affect therapeutic decisions, including the selection of DMARDs.Patient Care: Explore the importance of a comprehensive approach to treating psoriatic disease, addressing both the primary condition and associated health issues.Key Points & Highlights:Definitions and Importance: Clear definitions of comorbidities and related conditions, and their significance in the clinical setting.Treatment Influences: How the presence of comorbidities can alter the choice of therapies and the necessity of personalized treatment plans.Common Comorbidities: Discussion on obesity, cardiovascular disease, depression, and more, and their implications for patient care.Future Directions: The need for ongoing research and proactive management strategies to improve patient outcomes.Why listen?Educational Insight: Gain a deeper understanding of how comorbidities and related conditions impact psoriatic disease.Expert Opinions: Benefit from the knowledge and experience of leading specialists in the field.Comprehensive Care: Learn about the holistic approach to managing psoriatic disease, ensuring better quality of life for patients.Stay Connected:For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode! Hosted on Acast. See acast.com/privacy for more information.

Today on Inside GRAPPA, host Sebastian Herrera is joined by Lourdes Perez Chada, an Instructor in Dermatology at Harvard Medical School and a clinical investigator at the Brigham and Women's Hospital in Boston, and Cheryl Rosen who is the Head of the Division of Dermatology,Toronto Western Hospital and University Health Network Hospitals, a Clinician Investigator at Toronto Western Hospital, and a Professor of the Dept of Medicine, University of Toronto.In this episode, we discuss the importance of nail psoriasis, including the prevalence, manifestations, and diagnosis, and how it affects patients in their daily lives.Key Topics:Prevalence and Diagnosis: Nail psoriasis affects about 50% of patients with psoriasis and up to 90% over their lifetime. The experts discuss clinical diagnostic methods and the challenges in identifying the condition. Tools like biopsies and imaging are rarely used due to their invasiveness.Differential Diagnosis: They examine common conditions that can be mistaken for nail psoriasis, including onychomycosis (fungal infections), lichen planus, and alopecia areata.Impact on Quality of Life: Nail psoriasis has a significant impact, especially in terms of physical pain, mental health, and daily activities. Patients may experience anxiety and depression, particularly when their hands or feet are affected.Association with Psoriatic Arthritis: Nail psoriasis is a risk factor for developing psoriatic arthritis, due to the anatomical connection between the nail and underlying bones. The discussion covers how this link affects prognosis and treatment.Treatment Options: Historically difficult to treat, nail psoriasis management ranges from doing nothing for mild cases to topical treatments and biologics. The experts focus on biologics like Ixekizumab and Tofacitinib (Xeljanz), which have shown promise in treating both nail disease and psoriatic arthritis.Stay Connected For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode! Hosted on Acast. See acast.com/privacy for more information.

Join us in this episode of Inside GRAPPA, where our host Dr. Sebastian Herrera delves into the complexities of dactylitis in psoriatic disease. Dr. Herrera is joined by two renowned experts, Dr. Philip Helliwell and Dr. Sibel Aydin, who bring their extensive knowledge and insights to this fascinating topic.What's inside this episode?Understanding Dactylitis: Learn about the definition, prevalence, and clinical significance of dactylitis in psoriatic arthritis.Differential Diagnosis: Discover the differential diagnoses and the importance of distinguishing dactylitis from other conditions.Diagnostic Techniques: Explore the role of clinical examination and ultrasound in diagnosing and understanding the underlying pathology of dactylitis.Treatment Approaches: Gain insights into the current treatment recommendations for managing dactylitis in psoriatic disease, including local and systemic therapies.Key Highlights:Expert Insights: Dr. Helliwell discusses the clinical features, differential diagnosis, and the importance of dactylitis as a severity marker.Ultrasound Imaging: Dr. Aydin explains the use of ultrasound in identifying various pathologies associated with dactylitis, including synovitis, tenosynovitis, and entheseal involvement.Treatment Strategies: Both experts share their perspectives on the efficacy of different treatments, including the use of local steroid injections and systemic therapies like methotrexate and biologics.Why listen?Educational Value: Enhance your understanding of dactylitis and its management in psoriatic disease.Expert Opinions: Benefit from the knowledge and experience of leading experts in the field.Practical Insights: Learn practical tips for diagnosing and treating dactylitis effectively.Stay ConnectedFor more insightful episodes and updates, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share this episode with colleagues and friends who might find it beneficial! Hosted on Acast. See acast.com/privacy for more information.

Today on Inside GRAPPA, host Fabian Proft is joined by Professor Elaine Husni and Professor Stefan Siebert to discuss the management of conditions related to psoriatic arthritis (PSA), particularly inflammatory bowel disease (IBD) and uveitis. In this episode, we discuss treatment modalities, the importance of early diagnosis, and the implications for clinical practice. The experts also delve into future directions for PSA treatment, highlighting the evolving field of biologics and interdisciplinary approaches. This episode offers a comprehensive exploration of managing associated conditions in PSA, emphasizing the importance of personalized treatment strategies.What's inside this episode?Understanding Psoriatic Arthritis: Insights into managing associated conditions like IBD and uveitis.Expert Discussions: Professors Husni and Siebert share their experiences and approaches in treating these complex cases.Future of Treatment: An overview of emerging therapies and the importance of interdisciplinary collaboration in PSA management.Clinical Perspectives: Exploring the impact of early diagnosis and treatment personalization on patient outcomes.Stay Connected For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode! Hosted on Acast. See acast.com/privacy for more information.

In this insightful episode, our host and moderator Dr. Charlotte Gollins dives deep into the complexities and nuances of the 2022 GRAPPA Treatment Recommendations for the skin psoriasis domain, alongside experts Dr. Kristina Duffin and Dr. Joseph Merola.What's inside this episode?Behind the Scenes: Get an exclusive look into the rigorous process of developing the GRAPPA treatment recommendations.Challenges and Innovations: Explore the unique challenges faced in formulating guidelines for a complex disease like psoriatic arthritis.Expert Insights: Hear from Dr. Duffin and Dr. Merola as they share their experiences and the key focus areas in the development process of the skin domain.Future Directions: Learn about the aspirations for future updates to these crucial guidelines and how they aim to continuously evolve to meet patient needs.Join us for a deep dive into:The multifaceted approach to treating psoriasis.Balancing evidence-based guidelines with practical clinical application.The ongoing journey to refine and improve treatment recommendations.Why listen?Educational Insight: Understand the latest advancements in psoriasis treatment.Expert Opinions: Gain valuable knowledge from leading experts in the field.Global Impact: Discover how these guidelines are shaping psoriatic arthritis care worldwide.Stay Connected: For more intriguing insights and episodes, visit our website. Don't forget to subscribe to Inside GRAPPA for more episodes like this. Share with your colleagues and friends who might benefit from this episode! Hosted on Acast. See acast.com/privacy for more information.

Explore the realm of enthesitis and its treatment advancements in this informative episode of Inside GRAPPA. With renowned experts, Philip Mease (USA) and Dr. Lihi Eder (Canada), we journey through the intricacies of these diseases, emphasizing the manuscript "Management of Enthesitis in Patients with Psoriatic Arthritis." Discover the essence of Enthesitis, the challenges in its diagnosis, and the promising horizon of treatments. Stay curious as we unravel the complexities of this intriguing topic together!Key Highlights:Manuscript Spotlight: "Management of Enthesitis in Patients with Psoriatic Arthritis" - A comprehensive paper spotlighting the advancements and current insights on psoriatic arthritis and enthesitis.Understanding Enthesitis: The essence and impact of Enthesitis in the medical landscape. The diagnostic challenges and the role of ultrasound in offering a game-changing solution.Journey through Treatments:Historical insights into enthesitis and the tools, like the Leeds Enthesitis Index and SPARC, that have transformed our understanding over the last 25 years.The evolution of treatments, what the present offers, and a sneak peek into the future of psoriatic arthritis treatment.Unveiling the Future: The burning questions surrounding the pathophysiology of Enthesitis and the unmet needs in its management. The promising direction of current research and what it aims to achieve.Resources and Links: Manuscript: Management of Enthesitis in Patients with Psoriatic Arthritis. Organizations: CorEvitas Cohort - Delve deeper into the studies that shape our understanding of enthesitis. Hosted on Acast. See acast.com/privacy for more information.

Dive deep into the intricate world of psoriasis and psoriatic arthritis with experts Prof. Dafna Gladman and Prof. Ennio Lubrano. This episode focuses on the latest research, insights, and breakthroughs, with an in-depth exploration of the manuscript "Management of Axial Disease in Patients with Psoriatic Arthritis." Join us as we navigate the nuances and challenges of axial psoriatic arthritis, its distinction from ankylosing spondylitis, and the complexities of treatment choices. Stay curious, and let's uncover the mysteries of this fascinating topic together!Key Highlights:Manuscript Spotlight: "Management of Actual Disease in Patients with Psoriatic Arthritis" -- a vital paper highlighting the advancements and current understanding of axial psoriatic arthritis.Axial PsA Exploration:Historical perspective of Axial PsA and its progression.Differences between psoriatic arthritis with axial disease and ankylosing spondylitis.Radiographic features, MRI in diagnosis, and the AXIS trial's significance.Treatment Landscape:The current treatments available and the challenges of determining the best treatment.Addressing similarities and differences in treatment approaches for axial psoriatic arthritis and axial spondyloarthritis.Future Perspectives:The need for further research and clarity in defining axial psoriatic arthritis.The anticipation around the STAR study results and their implications.Resources and Links:Organization: Spondyloarthritis Research Consortium Canada (SPARCC).Studies:AXIS trial (Axial Psoriatic Arthritis)The STAR studyPublication: Article on early stages of axial psoriatic arthritis published in the Annals.Stay Connected: Visit our official GRAPPA website for more resources and episodes. Hosted on Acast. See acast.com/privacy for more information.

In this enlightening episode of Inside GRAPPA, we delve deep into the intricate world of peripheral arthritis in psoriatic disease. Today's host, Dr. Sebastian Herrera, is joined by the esteemed Dr. Katy Leung, and Professor Oliver Fitzgerald to discuss the significance, manifestation, and management of peripheral arthritis in patients with psoriatic disease.Dr. Herrera is a rheumatologist at Clínica Las Américas Auna and ARTMEDICA in Medellín, Colombia and also an Associate Professor of Rheumatology at Universidad CES and a member of Young GRAPPA. Dr. Leung is an Associate Professor at Singapore General Hospital and Duke-NUS Medical School in Singapore. Dr. Leung has interest in clinical and translational research in PsA, is the co-chair of the GRAPPA-OMERACT Outcome Measure Working group, and is also a member of the GRAPPA Education Committee. Dr. Fitzgerald is based at University College Dublin and has a major interest in clinical and translational research in PsA. More recent studies have explored genetic factors and biomarker development. Dr. Fitzgerald has been involved for many years with GRAPPA and took up the office of co-President in July 2021. He has been advocating for grant application opportunities addressing critical unmet needs in PsA for some time and this has culminated in the award of the first, significant, joint EU/industry funded Innovative Medicines Initiative (IMI) grant in PsA, the HIPPOCRATES consortium.

Welcome to the inaugural episode of Inside GRAPPA, where we delve into the latest research and development on psoriatic diseases.This episode takes you behind the scenes of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), sharing the meticulous process of creating these vital guidelines.In our inaugural episode, we bring together experts Laura Coates, Artie Kavanaugh, and Enrique Soriano along with Moderator Fabian Proft. They provide their unique perspectives on the creation, implementation, and future of the GRAPPA guidelines. This comprehensive framework is changing lives by reducing disease activity and managing symptoms, and you'll get to hear firsthand how it's evolved. Visit our website at grappanetwork.org to learn more. Hosted on Acast. See acast.com/privacy for more information.

Welcome to Inside GRAPPA, a podcast and brought to you by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Our mission is to enhance understanding and treatment of psoriasis and psoriatic arthritis through the sharing of research, knowledge, and collaborative efforts​.We bring together leading rheumatologists, dermatologists, scientists, patient representatives, and industry partners, uniting our passions to make a difference for those living with these conditions​.Join our host Fabian Proft as we navigate the challenges, share the latest research, and explore the triumphs in the world of psoriasis and psoriatic arthritis. Together, we can make a difference. Hosted on Acast. See acast.com/privacy for more information.